Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New online tool aims to ease tough prostate cancer decisions

NCT ID NCT07135271

Knowledge-focused Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether a new online tool, called BeSpoke, helps men with newly diagnosed localized prostate cancer make better treatment decisions. The tool gives personalized information about different treatments and their likely outcomes. Researchers will compare men who use the tool plus standard counseling to those who get standard counseling alone, measuring how conflicted they feel about their choice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bespoke Decision Support tool (online patient decision aid)
What this could lead to
If it works, this tool could help men with prostate cancer feel more confident and less conflicted when choosing their treatment.
What could go wrong
This is a relatively small, early-stage trial focused on decision-making, not on curing cancer. The tool may not improve outcomes for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 346 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Patient-Participants: 1. Newly diagnosed localised prostate cancer 2. Clinically suitable for at least two of the following treatment options: 1. active surveillance 2. focal therapy 3. radical prostatectomy 4. external beam radiotherapy 3. Willing and able to provide informed consent Exclusion Criteria for Patient Participants: 1. Unsuitable for active treatment due to very low risk prostate cancer or significant health issues. 2. Suspicion of metastatic prostate cancer based on clinical or imaging evidence including: 1. Imaging identified suspicious lesion on bone scan, CT, whole-body MRI or PSMA-PET/CT; 2. PSA ≥50 ng/mL. 3. Not able to provide informed consent. 4. Insufficient English proficiency for adequate use of BeSpoke Decision Support. (Patients with support from a family member, friend or partner, to overcome lack of English proficiency will be included.) 5. Enrolled in other localised prostate cancer studies where treatment is assigned rather than chosen by participants, e.g. PART Trial (Partial prostate Ablation vs Radical prostaTectomy) Inclusion criteria for Health Care Professionals: 1. Have seen BeSpoke Decision Support and spoken to patients in the intervention arm. 2. Willing and able to provide written or electronic informed consent Exclusion criteria for Health Care Professionals 1\. No experience of BeSpoke Decision Support.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localised prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Localised prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University College London Hospitals NHS Foundation Trust

    RECRUITING

    London, NW1 2BU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.